Avidity Partners Management LP Zai Lab LTD Transaction History

Avidity Partners Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$22.28 - $38.71 $26.8 Million - $46.6 Million	-1,202,691 Reduced 97.46%	31,309 $961,000
Q3 2022 Nov 14, 2022	BUY	$34.2 - $51.69 $42.2 Million - $63.8 Million	1,234,000 New	1,234,000 $42.2 Million
Q4 2021 Feb 14, 2022	SELL	$54.9 - $105.21 $1.95 Million - $3.75 Million	-35,600 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$105.0 - $178.37 $6.76 Million - $11.5 Million	-64,400 Reduced 64.4%	35,600 $3.75 Million
Q2 2021 Aug 16, 2021	BUY	$125.11 - $180.0 $12.5 Million - $18 Million	100,000 New	100,000 $17.7 Million

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.59B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.